Advanced Oncotherapy #AVO – Final Results statement plus CEO and Chairmans report

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2017, another year of significant technological development and installation of the Company’s first LIGHT system. Key highlights: ·     Successful integration of three of the four key LIGHT system structures significantly reducing technical […]

Nicolas Serandour, CEO of Advanced Oncotherapy #AVO discusses Yantai deal & £37m equity investment with BRR Media

Nicolas Serandour, CEO of Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, announces that they have signed an exclusive distribution agreement with Yantai CIPU Medical Technology to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. At the same time, the Company has secured £20.9 […]

Advanced Oncotherapy #AVO – Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of £37m

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an exclusive distribution agreement with Yantai CIPU Medical Technology Co. Ltd. to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. Under the agreement, Yantai CIPU will make a payment of £16.5 […]

Advanced Oncotherapy (AVO) – Interim results announcement

Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces its unaudited results for the six months ended 30 June 2017 and post-period events.  Highlights: ·     Technological milestones reached with successful integration and testing of proton source, RFQ and SCDTL significantly de-risking development process ·     Progress at the Harley Street […]

Advanced Oncotherapy (AVO) LIGHT machine trials confirm system on track to treat tumours by end Q3 2018

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, with successful integration of three key elements of the device. The first Side Coupled Drift Tube Linac (“SCDTL”) accelerating module has been integrated with the Radiofrequency Quadrupole […]

Advanced Oncotherapy (AVO) – Technological milestones update – CCL units

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the completion of a further technological milestone in the manufacture of its first LIGHT system. Delivery of CCLs The Company confirms that the final Coupled Cavity Linac (CCL) module, to be used to generate a beam capable of treating superficial […]

AVO – More LIGHT at the end of the tunnel – Wall Street Wires

by Spekulator at Wall Street Wires Quick reminder. I am an active investor into smaller companies where I see (a) genuine value (b) good management (c) an unusual or groundbreaking product. Mostly a,b and c have to be present and correct, but I will make exceptions. I am invested into companies listed on Nasdaq, London […]